Pre-market trading for ImmunityBio, Inc. (NASDAQ: IBRX) shows a noteworthy continuation of the company’s current rising trend. As of the last check, IBRX stock was increasing by 5.46% during pre-market session to $4.44 after closing at $4.21 the previous day with a significant rise of 21.68%. This spike comes after the first dosage in a clinical trial was announced, which greatly increased investor confidence.
CAR-NK Cell Therapy Pioneering
ImmunityBio’s (IBRX) clinical advances are highlighted by the start of a groundbreaking investigation to assess the efficacy of IBRX’s CAR-NK cell therapy, which precisely targets CD-19, for the treatment of non-Hodgkin’s lymphoma (NHL).
The QUILT 106 trial will examine the efficacy and safety of CD19-targeted high-affinity natural killer (t-haNK) cells. They will be examined first as a monotherapy and then in conjunction with the standard NHL treatment, rituximab. For this phase 1 open-label experiment, up to 10 participants are needed from Johannesburg, Pretoria, and Bloemfontein, South Africa.
Addressing a Critical Healthcare Need
Being the first cellular-targeted natural killer (NK) cell treatment research carried out in South Africa, this trial represents an important milestone. Non-Hodgkin’s lymphoma is the sixth most prevalent cancer in Sub-Saharan Africa, the fourth most frequent illness in men, and the fifth most common in women, according to the Cancer Association of South Africa. This investigation may provide important clinical insights given the high diagnostic rates and lack of approved therapies in the area.
Future Prospects and Implications
The QUILT 106 trial is pivotal for ImmunityBio, representing its inaugural clinical study of the CAR-NK, CD19 t-haNK cell line and its first investigation into liquid tumors. The company has undertaken this research in response to the often-overlooked Sub-Saharan African populations, highlighting the pressing need for innovative immunotherapies in the area.
Full patient enrollment for this Phase 1 study is anticipated by the first quarter of 2025, with topline data expected in the latter half of the same year. This study parallels U.S.-based QUILT 3.092 trial of ImmunityBio, reinforcing the company’s commitment to advancing cancer treatment options globally.
